CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC) today announced that, effective on
May 1, 2021, the Compensation
Committee of Blueprint Medicines' Board of Directors granted
non-qualified stock options to purchase an aggregate of 21,045
shares of its common stock and an aggregate of 10,520 restricted
stock units (RSUs) to 13 new employees under Blueprint Medicines'
2020 Inducement Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules.
The options have an exercise price of $96.32 per share, which is equal to the closing
price of Blueprint Medicines' common stock on April 30, 2021. Each option will vest as to 25%
of the shares underlying such option on the first anniversary of
the grant date and as to an additional 1/48th of the shares
underlying the option monthly thereafter, in each case,
subject to each such employee's continued employment on each
vesting date. Each RSU will vest as to 25% of the shares underlying
the RSU award on the first anniversary of the grant date and as to
an additional 25% of the shares underlying the RSU award annually
thereafter, subject to each such employee's continued employment on
each vesting date. The options and RSUs are subject to the terms
and conditions of Blueprint Medicines' 2020 Inducement Plan, and
the terms and conditions of the stock option and RSU agreement
covering the grant.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and
hematologic disorders. Applying an approach that is both precise
and agile, we create medicines that selectively target genetic
drivers, with the goal of staying one step ahead across stages of
disease. Since 2011, we have leveraged our research platform,
including expertise in molecular targeting and world-class drug
design capabilities, to rapidly and reproducibly translate science
into a broad pipeline of precision therapies. Today, we are
delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple
programs for genomically defined cancers, systemic mastocytosis,
and cancer immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on
Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301284885.html
SOURCE Blueprint Medicines Corporation